Krahn Joseph M, Jackson Michael R, DeRose Eugene F, Howell Elizabeth E, London Robert E
Laboratory of Structural Biology, MR-01, National Institute of Environmental Health Sciences, National Institutes of Health, Box 12233, Research Triangle Park, North Carolina 27709, USA.
Biochemistry. 2007 Dec 25;46(51):14878-88. doi: 10.1021/bi701532r. Epub 2007 Dec 4.
Type II dihydrofolate reductase (DHFR) is a plasmid-encoded enzyme that confers resistance to bacterial DHFR-targeted antifolate drugs. It forms a symmetric homotetramer with a central pore which functions as the active site. Its unusual structure, which results in a promiscuous binding surface that accommodates either the dihydrofolate (DHF) substrate or the NADPH cofactor, has constituted a significant limitation to efforts to understand its substrate specificity and reaction mechanism. We describe here the first structure of a ternary R67 DHFR.DHF.NADP+ catalytic complex, resolved to 1.26 A. This structure provides the first clear picture of how this enzyme, which lacks the active site carboxyl residue that is ubiquitous in Type I DHFRs, is able to function. In the catalytic complex, the polar backbone atoms of two symmetry-related I68 residues provide recognition motifs that interact with the carboxamide on the nicotinamide ring, and the N3-O4 amide function on the pteridine ring. This set of interactions orients the aromatic rings of substrate and cofactor in a relative endo geometry in which the reactive centers are held in close proximity. Additionally, a central, hydrogen-bonded network consisting of two pairs of Y69-Q67-Q67'-Y69' residues provides an unusually tight interface, which appears to serve as a "molecular clamp" holding the substrates in place in an orientation conducive to hydride transfer. In addition to providing the first clear insight regarding how this extremely unusual enzyme is able to function, the structure of the ternary complex provides general insights into how a mutationally challenged enzyme, i.e., an enzyme whose evolution is restricted to four-residues-at-a-time active site mutations, overcomes this fundamental limitation.
II型二氢叶酸还原酶(DHFR)是一种由质粒编码的酶,可赋予细菌对靶向DHFR的抗叶酸药物的抗性。它形成一个具有中央孔的对称同四聚体,该中央孔作为活性位点。其不同寻常的结构导致了一个混杂的结合表面,该表面可容纳二氢叶酸(DHF)底物或NADPH辅因子,这对理解其底物特异性和反应机制的努力构成了重大限制。我们在此描述了三元R67 DHFR.DHF.NADP+催化复合物的首个结构,分辨率为1.26 Å。该结构首次清晰地展示了这种缺乏I型DHFR中普遍存在的活性位点羧基残基的酶是如何发挥功能的。在催化复合物中,两个对称相关的I68残基的极性主链原子提供了识别基序,它们与烟酰胺环上的羧酰胺以及蝶啶环上的N3 - O4酰胺官能团相互作用。这组相互作用将底物和辅因子的芳香环以相对内向的几何结构排列,其中反应中心紧密相邻。此外,由两对Y69 - Q67 - Q67' - Y69'残基组成的中央氢键网络提供了一个异常紧密的界面,该界面似乎充当了一个“分子夹”,将底物以有利于氢化物转移的方向固定到位。除了首次清晰地揭示这种极其特殊的酶是如何发挥功能的之外,三元复合物的结构还为理解一种受到突变挑战的酶,即一种其进化仅限于一次四个残基的活性位点突变的酶,如何克服这一基本限制提供了一般性的见解。